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BRIEF REPORT
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ABSTRACT
Secretory immunoglobulin A (IgA) interacts with intestinal microbiota and promotes mucosal 
homeostasis. IgA-bacteria interactions are altered during inflammatory diseases, but how these 
interactions are shaped by bacterial, host, and environmental factors remains unclear. In this study, 
we utilized IgA-SEQ to profile IgA-bound fecal bacteria in 48 recurrent Clostridioides difficile patients 
before and after successful fecal microbiota transplantation (FMT) to gain further insight. Prior to 
FMT, Escherichia coli was the most highly IgA-targeted taxon; following restoration of the micro-
biota by FMT, highly IgA-targeted taxa included multiple Firmicutes species. Post-FMT IgA-targeting 
was unaffected by the route of FMT delivery (colonoscopy versus capsule), suggesting that both 
methods lead to the establishment of healthy immune–bacterial interactions in the gut. 
Interestingly, IgA-targeting in FMT recipients closely resembled the IgA-targeting patterns of the 
donors, and fecal donor identity was significantly associated with IgA-targeting of the recipient 
microbiota. These data support the concept that intrinsic bacterial properties drive IgA recognition 
across genetically distinct human hosts. Together, this study suggests that IgA-bacterial interac-
tions are reestablished in human FMT recipients to resemble that of the healthy fecal donor.
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Introduction
The mucosal antibody immunoglobulin A (IgA) helps 
to maintain homeostasis of the intestinal microbiota. 
IgA excludes pathogens, promotes the adhesion of com-
mensals, and alters microbial gene expression, shaping 
both the composition and the function of the 
microbiota.1 IgA-bacterial interactions are often highly 
strain-specific, differentiating between closely related 
amplicon sequence variants (ASVs).2–4 However, the 
factors which determine these IgA-bacterial interactions 
in the human gut remain poorly understood. IgA- 
targeting patterns are conserved between human feces 
and gnotobiotic mouse recipients, suggesting that intrin-
sic bacterial properties drive antibody recognition.2,4,5 
Mouse genotype also influences IgA-microbiota recog-
nition, however, through variation in major histocom-
patibility complex (MHC) binding and other immune 
factors.6–8 Further, environmental factors such as host 
nutrition have been recently shown to influence IgA- 
bacterial binding in mice.3 IgA-targeting of the human 
microbiota is altered during inflammatory diseases and 
undernutrition,2,9–11 but the extent to which these 
changes are driven by bacterial properties, host immu-
nity, or environmental factors is unknown.
When intestinal homeostasis is disrupted due to 
repeated antibiotic exposure, the gut ecosystem 
becomes susceptible to Clostridioides difficile, 
a major cause of hospital-acquired and recurrent 
infections in North America and Europe.12,13 Fecal 
microbiota transplant (FMT) from healthy donors 
is the most effective treatment for recurrent 
C. difficile infection (rCDI), as it restores a diverse 
microbial community and associated colonization 
resistance.14–16 FMT has also allowed researchers to 
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study the establishment of intestinal microbial 
communities in humans. Interestingly, the micro-
biota of FMT recipients is an emergent mixture of 
donor strains and preexisting patient strains, and 
its composition can be successfully predicted by 
machine learning techniques.17,18 The establish-
ment of IgA–microbiota interactions in the 
human intestinal tract following FMT has never 
been studied.
Here we characterize the IgA-targeted micro-
biota before and after FMT from 48 of 116 patients 
who participated in a clinical trial and were rando-
mized to either colonoscopy or oral capsule deliv-
ered FMT for rCDI.14 We evaluate the influence of 
delivery method, donor and pre-transplant micro-
biota, host anthropometrics, and systemic metabo-
lites on IgA-bacterial targeting in FMT recipients. 
The dysbiotic microbiota of pre-FMT rCDI 
patients was characterized by IgA-bound E. coli, 
similar to observations in other inflammatory 
intestinal conditions. In contrast, post-FMT recipi-
ents exhibited a diverse community of IgA-bound 
bacteria that included multiple Firmicutes. IgA- 
targeting was not influenced by delivery method, 
indicating that both colonoscopy and oral capsule 
lead to the establishment of healthy immune–bac-
terial interactions in the fecal microbiota. 
Furthermore, IgA-targeting patterns in FMT reci-
pients closely resemble that of their donors, sug-
gesting that intrinsic bacterial properties determine 
IgA–microbiota interactions in the human 
intestine.
Results
IgA responses before and after FMT
Fecal samples from 48 randomly selected patients 
recruited from Edmonton and cured of rCDI were 
obtained before and after FMT.14 IgA-targeting of 
the microbiota was quantified by IgA-SEQ: briefly, 
fecal bacteria were sorted into IgA-positive (IgA+) 
and IgA-negative (IgA-) populations by flow cyto-
metry, and subsequently characterized by 16S 
rDNA amplicon sequencing to identify IgA-bound 
bacteria.3,10 After filtering and rarefaction, a total of 
36 patients (mean [SD] age, 57.9 [18.5] y; 22 women 
[61%]; 17 [47%] colonoscopy-delivered FMT; 1 
patient had underlying ulcerative colitis and 1 had 
Crohn’s disease) had high-quality 16S data in both 
sorted fractions pre- and post-FMT. An IgA Index 
was calculated as previously described,3,10 repre-
senting the enrichment of bacteria in the IgA+ 
fraction compared to the IgA- fraction (see 
Methods for further details). For comparison with 
the IgA Index, we further estimated overall relative 
abundance of each taxon as its combined abun-
dance in the IgA+ and the IgA- sorted fractions.
As expected, the total microbiota of rCDI patients 
pre-FMT exhibited patterns of antibiotics-driven 
dysbiosis, including very low alpha-diversity (Fig 
S1A), enrichment of E. coli (Fig S1B) and separation 
from healthy donors by principle coordinate analysis 
(PCoA) (Fig S1C). We did not detect C. difficile in 
the pre-FMT gut in this dataset, likely due to vanco-
mycin suppression all patients received before trans-
plantation. In FMT recipients, alpha diversity was 
increased to more closely resemble that of the fecal 
donors (Fig S1A), and there was a substantial shift in 
microbiota composition reflecting the restored 
abundances of multiple Firmicutes and 
Bacteroidetes members (Fig S1B-C). These data are 
consistent with previous characterizations of the 
total microbiota in rCDI patients before and after 
FMT.14–16
The proportion of fecal bacteria bound by IgA 
was not different between donors and pre- or post- 
transplant patients (Figure 1(a)). However, broad 
changes in IgA-targeting were apparent before and 
after FMT, according to a principle component 
analysis (PCA) of the IgA Index (Figure 1(b), 
p = .001 by PERMANOVA). Prior to FMT, E. coli 
was the most highly IgA-targeted member of the 
fecal microbiota, as defined by an IgA Index sig-
nificantly greater than zero (Figure 1(c)). Following 
FMT, several Firmicutes members were among the 
most IgA-targeted taxa, including Ruminococcus 
and Dorea (Figure 1(d)). E. coli is known to be 
highly IgA-targeted in the inflamed intestine,9,10 
whereas Firmicutes species in general, and 
Ruminococcus and Dorea in particular, are com-
mon targets of IgA in healthy adults.5,19 Overall, 
these data suggest that healthy IgA–microbiota 
interactions are restored in rCDI patients following 
FMT.
Importantly, IgA-targeting reflects immune 
recognition of bacteria independently of their taxo-
nomic abundance. IgA-targeting in FMT recipients 
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was dependent on strain identity and varied 
between closely related ASV, including many abun-
dant yet IgA-negative strains (Fig S2A-B). Indeed, 
consistent with previous reports, there was no cor-
relation between taxonomic abundance and IgA- 
targeting in this dataset (Fig S2C-D). These data 
therefore indicate that in addition to total micro-
biota diversity, healthy IgA–microbiota interac-
tions are restored in rCDI patients following FMT.
IgA response by FMT delivery
FMT was delivered in this study via oral capsule or 
colonoscopy, which we previously showed did not 
have an impact on success of FMT or resultant 
composition of the microbiota.14 However, colonic 
and small intestinal IgA responses differ greatly; 
route of delivery could thus conceivably alter the 
initiation of an immune response. We confirm here 
that there were no differences in IgA-bacterial 
interactions by delivery method. Both capsule and 
colonoscopy recipients had comparable IgA-coating 
levels of the microbiota (Figure 2(a)). There was no 
difference in distribution of the IgA Index by deliv-
ery method according to PERMANOVA analysis 
(Figure 2(b); p > .05). Further, no ASV differed in 
abundance or IgA-targeting by Wilcoxon Rank Sum 
Test at FDR<0.1 (Figure 2(c)). These data suggest 
that the route of delivery does not influence fecal 
IgA-bacterial interactions post-FMT.
IgA responses are influenced by fecal donor
Post-FMT microbiota samples clustered together 
with donor samples by PCA analysis of the IgA 
Index (Figure 1(b)). Indeed, the majority of taxa 
showed similar IgA-targeting status between 
donors and FMT recipients (Figure 3(a), Fig 
S3A). This association was most notable for 
taxa which engrafted from the donor microbiota, 
(a) (b)
(c) (d)
Figure 1. Differences in IgA-targeting of the microbiota before and after FMT. (a) Percentage of IgA-positive (%IgA+) fecal bacteria in 
48 patients pre-FMT (Pre) and post-FMT (Post), and in 6 FMT donor samples from 4 individual donors. Significance determined by 
Kruskal-Wallis. (b) Principal Component Analysis based on Euclidean distance of the IgA Index. Significance determined by 
PERMANOVA. (c–d) Most highly IgA-targeted taxa pre-FMT (c) and post-FMT (d), as determined by an IgA Index significantly greater 
than zero by one-sided Wilcoxon rank sum test. Each data point in (c-d) represents an individual patient. In (b-d), n = 36 patients pre- 
and post-FMT, and n=5 donor fecal samples from 3 individual donors.
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i.e., taxa which were undetected in the pre-FMT 
patient microbiota but were detected in the 
donor and the post-FMT microbiota. For such 
‘donor taxa’, there was a strong correlation 
between donor IgA Index and post-FMT IgA 
Index (Figure 3(b)). For example, Ruminococcus 
torques was missing in pre-FMT patients, but 
was IgA-positive in the donors; both relative 
abundance and high IgA-recognition of this 
taxon were restored in patients post-FMT (Fig 
S3B-C).
In contrast, taxa that were detected in the dys-
biotic rCDI microbiota pre-FMT showed poor cor-
relation with donor IgA-targeting (Fig S3D). 
Instead, IgA-targeting of these ‘patient taxa’ after 
FMT correlated with their pre-FMT IgA-targeting 
(Figure 3(b)). For example, E. coli was highly IgA- 
targeted in pre-FMT patients, but was not bound by 
IgA in healthy fecal donors; rather than reverting to 
donor status, E. coli remained highly IgA-targeted 
in post-FMT patients (Figure 1(d), Fig S3E-F). The 
post-FMT microbiota is known to contain an emer-
gent mixture of patient and donor strains; although 
strain-level resolution is not possible in this dataset, 
we speculate that abundant patient strains persisted 
post-FMT and thus retained their IgA-targeting 
status.
Given the overall similarity of the recipient 
and donor IgA-targeting patterns, we next exam-
ined whether IgA-targeting of the post-FMT 
microbiome was associated with IgA-targeting 
of the individual donor microbiome. Four 
Figure 2. IgA-targeting of microbiota post-FMT by delivery method. (a) Percentage of IgA-positive (%IgA+) fecal bacteria in 48 FMT 
recipients (n = 23 capsule delivery and n = 25 colonoscopy delivery). Significance determined by Wilcoxon rank sum test. (b) Principal 
Component Analysis based on Euclidean distance of the IgA Index. Non-significant by PERMANOVA (p > .1). (c) Heatmap depicting 
average relative abundance and average IgA Index in post-transplant patients by delivery method. No taxa were significantly different 
between capsule and colonoscopy recipients, as determined by Wilcoxon rank sum test with FDR-corrected p-value < 0.05. Letters and 
numbers after the genus designate the first characters of a unique ASV code used by qiime2. For (b–c), n = 36 FMT recipients (n = 19 
capsule delivery and n = 17 colonoscopy delivery).
e1862027-4 K. E. HUUS ET AL.
different stool donors were used in this cohort; 
three donors had a large enough number of 
patient recipients for statistical analysis (n = 14, 
n = 12 and n = 9 FMT recipients with valid IgA 
Index data for donors 1, 2 and 3, respectively) 
and the fourth was excluded (n = 1 FMT recipi-
ent). As expected, the total microbiota was sig-
nificantly different between recipients of the 
three different stool donors. This included 
significant changes in both alpha- and beta- 
diversity, and in the relative abundance of many 
strains, between recipients of different FMT 
donors (Fig S4A-C).
The proportion of IgA-bound bacteria did not 
differ significantly in FMT recipients by donor 
identity (Fig S4D). However, there was 
a significant separation of samples by donor iden-
tity according to principle coordinate analysis of 
Figure 3. IgA-targeting of microbiota post-FMT is influenced by donor microbiota (a) Heatmap depicting average IgA-targeting of taxa 
in donors, pre- and post-transplant patients. A star (*) indicates taxa that were significantly different post-FMT compared to pre-FMT, as 
determined by paired Wilcoxon rank sum test with FDR-corrected p-value < 0.05. Letters and numbers after the genus designate the 
first characters of a unique ASV code used by qiime2. N = 36 patients pre- and post-FMT, and n = 5 donor fecal samples from 3 
individual donors. (b) Correlation between IgA Index of donors and post-FMT patients, for taxa that were detected in donors but not in 
pre-FMT patients. Each data point represents the average IgA Index of a single ASV. Significance determined by Spearman’s correlation. 
(c) Correlation between IgA Index of pre-FMT and post-FMT patients, for taxa that were abundant in pre-FMT patients. Each data point 
represents the average IgA Index of a single ASV. Significance determined by Spearman’s correlation. (d) Principal Coordinate Analysis 
based on Euclidean distance of the IgA Index post-FMT, by donor identity and patient sex. Significance determined by PERMANOVA. 
N = 35 FMT recipients (n = 14 of donor 1; n = 12 of donor 2; n = 9 of donor 3). FMT recipients from a fourth donor were excluded as the 
sample size was too small for statistical comparison (n = 1).
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the IgA Index (Figure 3(d); p = .01 by 
PERMANOVA analysis), indicating that overall 
IgA-targeting patterns also differ in the recipients 
of different fecal microbiotas. Several taxa showed 
significantly different IgA-targeting patterns in the 
recipients of the different fecal donors (Fig S4B). 
Only one of these, Ruminococcus ASV 16c, was 
differentially abundant in the same patients (Fig 
S4B). These data suggest that IgA-targeting pat-
terns vary according to the donor microbiota com-
position, but not necessarily as a result of altered 
taxonomic abundance. Rather, strain-specific dif-
ferences between ASV from different donors might 
explain the different IgA-targeting observed in 
recipients.
Importantly, since there was sex-matching 
between stool donor and recipient, testing for sex 
differences in post-FMT patients also yields similar 
differentially targeted taxa (Figure 3(d) and supple-
mental R markdown). We cannot, therefore, 
exclude the possibility that sex is a driver of IgA- 
targeting post-FMT, particularly as immune func-
tion is known to differ significantly between males 
and females.20 However, we did not see any differ-
ences in microbiota or IgA-targeting by sex prior to 
FMT (supplemental R markdown).
Collectively, we find that the IgA-targeting of the 
human microbiota after FMT is significantly influ-
enced by IgA-targeting of the donor microbiota. 
This is independent of taxonomic abundance itself, 
and may reflect other properties of the engrafted 
strains. Together, these data support the impor-
tance of intrinsic microbial properties in determin-
ing IgA-targeting patterns of the human 
microbiota.
Variability of IgA-targeted microbiota
To identify other factors which might influence 
IgA-targeting in FMT recipients, we performed 
a PERMANOVA analysis of the IgA Index across 
multiple host and metabolic variables. Patient age, 
weight (body mass index (BMI) prior to FMT, and 
weight loss associated with rCDI) and underlying 
IBD did not measurably influence the IgA Index in 
this dataset (Figure 4(a)).
Restoration of the fecal microbiota in rCDI 
patients correlates with systemic metabolite 
changes, including increases in circulating short 
chain fatty acids (SCFA), decreases in complexity 
of serum N-glycan structures, and decreases in 
serum selenium and copper levels.21–26 Since 
SCFA, glycosylation, and nutrition are known to 
impact IgA responses to the microbiota, we also 
looked for the impact of these metabolites on IgA- 
targeting (Figure 4(a)). However, no metabolite 
reached statistical significance by PERMANOVA 
after FDR correction. We did not find the IgA- 
targeting of any individual taxon to correlate sig-
nificantly with systemic metabolites, with the 
exception of a negative correlation between 
Pseudomonas veronii and nickel concentrations in 
post-FMT patients (Figure 4(b)). There were also 
several positive correlations between SCFA levels 
and the IgA-targeting of Firmicutes species post- 
FMT, which is interesting given that SCFA are 
known to stimulate IgA responses;27 however, 
these correlations did not pass FDR correction 
(Figure 4(c) and Supplemental R Markdown).
The correlations between IgA-targeting and spe-
cific metabolites observed here are interesting and 
warrant further study. However, the small sample 
size for analysis means that these associations 
should be interpreted with caution. Taken together, 
these data do not support a strong role for host or 
metabolic factors in determining microbiota IgA- 
targeting. We conclude that microbiota composi-
tion itself is a major determinant of IgA-targeting 
across genetically distinct human hosts.
Discussion
This is the first study to examine the changing 
patterns of IgA-targeted microbiota in rCDI 
patients before and after FMT. These findings con-
firm that in addition to broad changes in the total 
microbiota, IgA-bacterial interactions are pro-
foundly altered in rCDI patients. IgA-targeting of 
the microbiota is largely restored by FMT to resem-
ble that of the healthy fecal donor. Mode of delivery 
does not influence IgA-bacterial targeting in FMT 
recipients, consistent with the clinical efficacy of 
both methods; this provides further support of the 
use of either colonoscopy or capsule as a viable 
FMT delivery method.
Previous studies of IgA-targeting in human 
populations have noted high inter-individual 
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variability.5,11 It has been unclear whether this is 
driven by differences in microbiota composition, 
host genetics, diet, or a combination of factors. 
Here we show that IgA-bacterial binding patterns 
in FMT recipients closely resemble that of the 
donors and are influenced by donor identity. This 
is consistent with studies showing conserved IgA- 
binding patterns between fecal microbiota donors 
and gnotobiotic mouse recipients.5 Together, these 
data support the concept that specific bacterial 
properties shape IgA recognition of the human 
microbiota.
Notably, taxa that were abundant in patients 
prior to FMT retained their IgA-targeting status 
post-FMT. The microbiota of pre-FMT rCDI 
patients was characterized by highly IgA-targeted 
E. coli, and E. coli remained highly IgA-targeted 
after FMT despite low recognition of this taxon in 
healthy donor samples (Figure 3(a)). High IgA- 
targeting of E. coli has been observed in inflamma-
tory bowel disease patients and in children with 
severe acute undernutrition, and correlates with 
the presence of E. coli virulence factors; moreover, 
IgA-targeted E. coli strains have been shown to 
induce inflammation and intestinal damage when 
transplanted into gnotobiotic mice.2,9,10 Thus, the 
high IgA-targeting of E. coli observed here suggests 
expansion of pro-inflammatory pathobionts in the 
rCDI patients, which may not be fully cleared by 
FMT. Alternatively, IgA recognition of E. coli may 
reflect a heightened host immune response to 
E. coli in rCDI patients, which persists post-FMT 
despite engraftment of the donor microbiota. In the 
future, resolving strain-level taxonomic differences 
through deep metagenomic sequencing would help 
to differentiate donor and patient strains and thus 
provide improved understanding of IgA-targeting 
variation by bacterial identity. Given the 
Figure 4. Variability of IgA-targeted microbiota. (a) PERMANOVA analysis, based on Euclidean distance of the IgA Index, was performed 
on the full dataset (n = 77, including donor samples), or on pre- and post-transplant patients (n = 36). A star (*) indicates significance at 
FDR-correction <0.05. Color represents raw p value, and ‘coef’ is the coefficient of variance. Permutations were constrained by day of 
sorting to account for a possible batch effect. (b) Correlation between IgA Index of Pseudomonas veronii and serum nickel concentra-
tion in post-FMT patients. Linear fit is shown. Significant by Spearman’s correlation at FDR-adjusted p < .05. N=23. (c) Correlation 
between IgA Index of Erysipelotrichaceae and serum 2-hydroxy butyrate in post-FMT patients. Linear fit is shown. Significant by 
Spearman’s correlation at raw p <. 05 but does not pass FDR. N=16.
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importance of IgA in maintaining intestinal home-
ostasis, a better understanding of these interactions 
and their recovery after FMT could help improve 
the rational design of microbial therapies for rCDI 
infection.28
This study has several limitations. The study 
cohort consisted of a small sample size from 
a single center. Additionally, the donors were all 
drawn from a healthy Western population and 
often showed similar IgA-coating patterns; in con-
trast, important differences in both strain identity 
and IgA-targeting may exist between geographi-
cally distinct populations and by disease state.11 
Variation in IgA responses was poorly explained 
by available host and metabolite data, but the small 
sample size may have prevented the detection of 
more subtle influences on IgA-targeting. Also, 
although there was a significant effect of patient 
sex, this variable was inseparable from donor iden-
tity due to sex-matching of the patient and donor 
pairs. In the future, controlling for sex and account-
ing for host genetic and immune variation may be 
necessary to understand the role of the host in IgA- 
targeting of the microbiota.
IgA is fundamentally important in maintaining 
homeostasis of the intestinal microbiota, but the 
variation of IgA-targeting in health and disease 
remains poorly understood. This study shows that 
dysbiotic IgA-targeting of the microbiota in rCDI 
patients is largely, but not completely, restored by 
FMT. Furthermore, bacterial identity is a major 
determinant of IgA-targeting across unrelated 
human hosts. Together, these data provide valuable 
insights into immune recognition of the rCDI 
microbiota before and after FMT, and into our 
fundamental understanding of IgA-microbial 
homeostasis.
Materials and methods
Study participants and sample collection
Adult patients with at least 2 CDI recurrences were 
recruited in Alberta between 2014 and 2016 as 
previously described.14 Each patient was main-
tained on vancomycin suppression till 24 hours 
prior to the assigned FMT treatment. Stool samples 
were collected at screening (pre-FMT), and at 
4 weeks after FMT (post-FMT), and were stored 
at −80 C as previously reported. Ethical approval 
for this study was obtained by the Health Research 
Ethics Board, University of Alberta (Pro00049006) 
and the Clinical Research Ethics Board, University 
of British Columbia (H18-00880), and all patients 
provided informed consent.
IgA-sorting
IgA-sequencing was performed as described 
previously.3 Approximately 50 mg of each fecal 
sample (± 10 mg) was homogenized in 1 mL of 
phosphate-buffered saline (PBS; HyClone DPBS-/- 
, SH30028.02) and spun gently to settle debris; 
intestinal bacteria were then filtered through 
a 0.7 µm filter. A volume of suspension equal to 
5 mg of sample was washed in FACS buffer (PBS 
containing 1% bovine serum albumin) and 
blocked for 20 minutes in FACS buffer containing 
10% fetal bovine serum. Samples were then stained 
with anti-human IgA-PE (Miltenyl 130–093-128) 
or an isotype control (eBioscience, 12–4714-42) at 
1:25 dilution for 30 minutes in the dark. Samples 
were washed twice more and fixed overnight in 2% 
paraformaldehyde (PFA) at 4°C in the dark with-
out shaking. The next day, the PFA was washed off 
and samples were stained with SYTO-BC (1:4000 
dilution) for bacterial DNA, washed again and 
sorted by flow cytometry into IgA-positive (FITC 
+PE+) and IgA-negative (FITC+PE-) populations. 
A minimum of 50 000 events are collected in the 
IgA+ and IgA- fraction and frozen at −20°C for 
further analysis. Each sample was stained with 
both an anti-human IgA antibody and an isotype 
control, and the final percentage of IgA-positive 
bacteria was reported after subtraction of the iso-
type-positive population. Samples in which the 
isotype and antibody-specific populations could 
not be distinguished were excluded from further 
sequencing analysis.
Bioinformatics analysis of 16S rDNA data
Demultiplexed forward reads were analyzed in 
QIIME2 (https://qiime2.org/)29, using the Dada2 
option30 for sequence quality control and trimming 
to 250 bp. Taxonomic assignment was performed 
using the SILVA database.31 Further filtering was 
then performed in R using phyloseq.32 Filtering 
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included removal of unintended targets (archaea, 
mitochondria, and chloroplast) as well as common 
contaminants of Ig-SEQ datasets 
(Alphaproteobacteria),11,33 removal of singleton 
taxa, and rarefaction to 5000 reads.
A log-adjusted IgA index was calculated as 
described previously:3,10 
IgAIndex ¼   log IgA
þtaxonð Þ  log IgA  taxonð Þ
log IgAþtaxonð Þþlog IgA  taxonð Þ
� �
. 
A pseudocount of 0.0000001 relative abundance 
was added before log adjustment to allow for 
zero values. Positive IgA Index values (up to 
a maximum of 1.0) represent enrichment of 
a taxon in the IgA-positive-sorted fraction com-
pared to the IgA-negative fraction, i.e., IgA- 
targeting of the bacterium. Conversely, negative 
values (down to a minimum of −1.0) indicate 
depletion in the IgA-positive fraction, or lack of 
IgA-targeting.
Taxa were maintained at the ASV level for calculation 
of the IgA Index. IgA Index data was further filtered for 
prevalence within each pre-FMT and post-FMT dataset, 
by excluding taxa in which ≥75% of samples had zero 
values. Relative abundance was estimated by summing 
the IgA-positive and IgA-negative relative abundance. 
We did not find any evidence of a sorting batch effect on 
the IgA Index (Supplemental R Markdown). Raw 
sequencing data has been deposited to the Sequence 
Read Archive (SRA) under BioProject PRJNA650203.
16S rDNA library preparation
Sorted bacterial suspensions were boiled for 15 min at 
100°C and 2 µL of lysate was used as template for 16S 
PCR, using Illumina-tagged and barcoded primers spe-
cific for the 16S V4 region.34 PCR was performed with 
Phusion polymerase under the following cycling condi-
tions: 5 minutes initial denaturation at 98°C, 30 cycles of 
20 seconds at 98°C, 15 seconds at 55°C, 30 seconds at 72° 
C, and 10 minutes final extension at 72°C. Reactions 
were run on a gel to ensure successful amplification, and 
were purified and normalized using the 96well Sequel- 
Prep kit (ThermoFisher A1051001). All reactions were 
subsequently pooled and gel extracted (GeneJet K0692) 
to remover primer-dimers. Sequencing was performed 
on an Illumina MiSeq using a v2 kit for 2 × 250 bp reads 
with 30% PhiX at the Biomedical Research Center 
(BRC) Sequencing Core of the University of British 
Columbia.
Detection and quantification of short-chain fatty 
acids (SCFAs) in feces and serum
Targeted gas chromatography-mass spectrometry 
(GC-MS) for SCFA detection, identification, and 
quantification was performed using adaptation of 
previously described protocols for the analysis of 
samples of stool and serum.25,35,36 Samples analysis 
was performed on an Agilent 7890B GC system 
coupled to an Agilent 5977A mass selective detector 
(Agilent, USA). Analysis of data was performed 
using MassHunter software (Agilent), with SCFA 
concentrations being integrated from a freshly pre-
pared calibration curve for each standard.
Biometal profiling
Selected trace metal (iron, selenium, zinc, cadmium, 
cobalt, copper, magnesium, manganese, nickel, and 
lead) concentrations in plasma were determined by 
Inductively Coupled Plasma Mass Spectrometry (ICP- 
MS) analytical technique, using the ICPMS-2030 spec-
trometer (Shimadzu, Japan). Details regarding ICP-MS 
measurement conditions and parameters are described 
in previous studies.37 Briefly, 100 µL serum was digested 
in a combination of 300 µL nitric acid (70% purified by 
redistillation, Sigma-Aldrich), 100 µL hydrogen peroxide 
solution (25–35% for ultratrace analysis, Sigma Aldrich), 
and 100 µL hydrochloric acid (30% suprapure, Merck). 
Serial dilutions of ICP-Multi-element standard solution 
IV (Merck, Certipur) and ICP-MS selenium single stan-
dard solution (Sigma-Aldrich, TraceCERT) were used 
for calibration of all the biometals analytes. A certified 
reference material, BCR 637 (Institute for Reference 
Materials and Measurements) as well as reference mate-
rial ERM-DA120 (European Reference Materials) were 
analyzed to validate the calibration. A solution contain-
ing scandium, yttrium, terbium, tellurium, and rhodium 
(Sigma-Aldrich, TraceCERT) in 1% nitric acid was used 
as an internal standard (automatically added during 
analysis through T-piece).
Serum N-glycome analysis
Analysis of total serum N-glycome was performed 
as previously described.23 Briefly, serum N-glycans 
were enzymatically released from proteins by 
PNGase F, fluorescently labeled with 2-aminoben-
zamide, and cleaned-up from the excess of reagents 
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by hydrophilic interaction liquid chromatography 
solid phase extraction (HILIC-SPE), as previously 
described. Fluorescently labeled and purified 
N-glycans were separated by HILIC on a Waters 
BEH Glycan chromatography column, 
150 × 2.1 mm i.d., 1.7 μm BEH particles, installed 
on an Acquity ultra-performance liquid chromato-
graphy (UPLC) H-class system (Waters), consisting 
of a quaternary solvent manager, sample manager 
and a fluorescence detector set with excitation and 
emission wavelengths of 250 nm and 428 nm, 
respectively. Obtained chromatograms were sepa-
rated into 39 peaks. The amount of N-glycans in 
each chromatographic peak was expressed as 
a percentage of total-integrated area. From 39 
directly measured glycan peaks we calculated 12 
derived traits which average particular glycosyla-
tion traits like galactosylation, sialylation, and 
branching across different individual glycan struc-
tures and are, consequently, more closely related to 
individual enzymatic activities and underlying 
genetic polymorphisms. Derived traits used were: 
the proportion of low branching (LB) and high 
branching (HB) N-glycans, the proportion of a-, 
mono-, di-, tri- and tetra-galactosylated N-glycans 
(G0, G1, G2, G3 and G4, respectively), and a-, 
mono-, di-, tri- and tetra-sialylated N-glycans (S0, 
S1, S2, S3 and S4, respectively).
Statistical analysis
All statistical analysis was performed in R studio 
using the phyloseq and ggplot2 packages as indi-
cated in the attached R markdown file 
(Supplemental File 1). Data structure of the IgA 
Index was explored using a Principle Component 
Analysis based on Euclidean distance. 
A PERMANOVA analysis was iteratively applied 
to each variable of interest to determine its con-
tribution to the distribution of the IgA Index. 
Non-parametric Wilcoxon rank sum tests were 
used to compare data with two groups, and data 
were paired by patient for pre-FMT versus post- 
FMT comparisons. A one-sided Wilcoxon rank 
sum test was used to identify taxa with an IgA 
Index significantly different from zero. 
Spearman’s correlation was applied for continu-
ous variables, including serum metabolites. Unless 
otherwise indicated, multiple correction of 
statistical tests was applied using the False 
Discovery Rate (FDR).
Acknowledgments
We would like to thank all of the patients who participated in 
this study. We are further grateful to members of the Finlay lab 
for their suggestions and critical feedback. Work in B.B.F’s lab 
was supported by a Foundation grant from CIHR. K.E.H. was 
supported by a Vanier Canada Graduate scholarship from 
CIHR, a Killam Doctoral Fellowship, and a Four-Year 
Fellowship from the University of British Columbia. T.M.M. 
and D.K. were supported by an Alberta Health Services 
research grant and a University of Alberta Hospital 
Foundation research grant. B.H.M. was the recipient of a 
Medical Research Council (MRC) Clinical Research Training 
Fellowship and is the recipient of an NIHR Academic Clinical 
Lectureship. J.R.M. and B.H.M. are supported by the NIHR 
Imperial Biomedical Research Centre.
Funding
This work was supported by the Alberta Health Services (no 
grant number available) and Canadian Institute for Health 
Services (FDN-159935).
ORCID
Benjamin H Mullish http://orcid.org/0000-0001-6300-3100
Julian R Marchesi http://orcid.org/0000-0002-7994-5239
Tanya M Monaghan http://orcid.org/0000-0001-7622-3997
Dina Kao http://orcid.org/0000-0002-6096-0586
References
1. Pabst O, Slack E. IgA and the intestinal microbiota: the 
importance of being specific. Mucosal Immunol. 
2019;13(1): 12-21.
2. Palm NW, de Zoete MR, Cullen TW, Barry NA, 
Stefanowski J, Hao L, Degnan PH, Hu J, Peter I, 
Zhang W, et al. Immunoglobulin a coating identifies 
colitogenic bacteria in inflammatory bowel disease. Cell. 
2014;158:1000–1010. doi:10.1016/j.cell.2014.08.006.
3. Huus KE, Bauer KC, Brown EM, Bozorgmehr T, 
Woodward SE, Serapio-Palacios A, Boutin RCT, 
Petersen C, Finlay BB. Commensal bacteria modulate 
immunoglobulin a binding in response to host 
nutrition. Cell Host & Microbe [Internet]. 2020 [cited 
2020 Apr 23];27: 909–921.e5. doi:10.1016/j. 
chom.2020.03.012.
4. Yang C, Mogno I, Contijoch EJ, Borgerding JN, 
Aggarwala V, Li Z, Siu S, Grasset EK, Helmus DS, 
Dubinsky MC, et al. Fecal IgA levels are determined 
by strain-level differences in bacteroides ovatus and are 
e1862027-10 K. E. HUUS ET AL.
modifiable by gut microbiota manipulation. Cell Host & 
Microbe [Internet]. 2020 [cited 2020 Feb 20]; 27:467– 
475.e6. doi:10.1016/j.chom.2020.01.016.
5. Planer JD, Peng Y, Kau AL, Blanton LV, Ndao IM, 
Tarr PI, Warner BB, Gordon JI. Development of the 
gut microbiota and mucosal IgA responses in twins and 
gnotobiotic mice. Nature [Internet]. 2016 [cited 2016 
May 26];534: 263–266. doi:10.1038/nature17940.
6. Kubinak JL, Stephens WZ, Soto R, Petersen C, Chiaro T, 
Gogokhia L, Bell R, Ajami NJ, Petrosino JF, Morrison L, 
et al. MHC variation sculpts individualized microbial 
communities that control susceptibility to enteric 
infection. Nat Commun. 2015;6:8642. doi:10.1038/ 
ncomms9642.
7. Fransen F, Zagato E, Mazzini E, Fosso B, Manzari C, El 
Aidy S, Chiavelli A, D’Erchia AM, Sethi MK, Pabst O, 
et al. BALB/c and C57BL/6 mice differ in polyreactive 
IgA abundance, which impacts the generation of 
antigen-specific IgA and microbiota diversity. 
Immunity. 2015;43:527–540. doi:10.1016/j. 
immuni.2015.08.011.
8. Cullender TC, Chassaing B, Janzon A, Kumar K, 
Muller CE, Werner JJ, Angenent LT, Bell ME, 
Hay AG, Peterson DA, et al. Innate and adaptive immu-
nity interact to quench microbiome flagellar motility in 
the gut. Cell Host Microbe. 2013;14:571–581.
9. Viladomiu M, Kivolowitz C, Abdulhamid A, Dogan B, 
Victorio D, Castellanos JG, Woo V, Teng F, Tran NL, 
Sczesnak A, et al. IgA-coated E. coli enriched in Crohn’s 
disease spondyloarthritis promote T H 17-dependent 
inflammation. Sci Transl Med. 2017;9:eaaf9655. 
doi:10.1126/scitranslmed.aaf9655.
10. Kau AL, Planer JD, Liu J, Rao S, Yatsunenko T, 
Trehan I, Manary MJ, Liu T-C, Stappenbeck TS, 
Maleta KM, et al. Functional characterization of 
IgA-targeted bacterial taxa from undernourished 
Malawian children that produce diet-dependent 
enteropathy. Sci Transl Med. 2015;7:276ra24–276ra24. 
doi:10.1126/scitranslmed.aaa4877.
11. Huus KE, Rodriguez-Pozo A, Kapel N, Nestoret A, 
Habib A, Dede M, Manges A, Collard J-M, 
Sansonetti PJ, Vonaesch P, et al. Immunoglobulin 
recognition of fecal bacteria in stunted and 
non-stunted children: findings from the Afribiota 
study. Microbiome. 2020;8:113. doi:10.1186/s40168- 
020-00890-1.
12. Abbas A, Zackular JP. Microbe-microbe interactions 
during Clostridioides difficile infection. Curr Opin 
Microbiol. 2020;53:19–25. doi:10.1016/j. 
mib.2020.01.016.
13. Tickler IA, Obradovich AE, Goering RV, Fang FC, 
Tenover FC, Consortium HAI. Changes in molecular 
epidemiology and antimicrobial resistance profiles of 
Clostridioides (Clostridium) difficile strains in the 
United States between 2011 and 2017. Anaerobe. 
2019;60:102050. doi:10.1016/j.anaerobe.2019.06.003.
14. Kao D, Roach B, Silva M, Beck P, Rioux K, Kaplan GG, 
Chang H-J, Coward S, Goodman KJ, Xu H, et al. Effect 
of oral capsule- vs colonoscopy-delivered fecal micro-
biota transplantation on recurrent clostridium difficile 
infection: a randomized clinical trial. JAMA. 
2017;318:1985–1993. doi:10.1001/jama.2017.17077.
15. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, 
Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, 
Bartelsman JFWM, Tijssen JGP, et al. Duodenal infu-
sion of donor feces for recurrent Clostridium difficile. 
New England J Medi. 2013;368:407–415. doi:10.1056/ 
NEJMoa1205037.
16. Kelly CR, Khoruts A, Staley C, Sadowsky MJ, Abd M, 
Alani M, Bakow B, Curran P, McKenney J, Tisch A, 
et al. Effect of Fecal microbiota transplantation on 
recurrence in multiply recurrent clostridium difficile 
infection: a randomized trial. Ann Intern Med. 
2016;165:609–616. doi:10.7326/M16-0271.
17. Smillie XR, Alm EJ, Gevers D, Friedman J, Sung J, 
Youngster I, Hohmann EL, Staley C, Khoruts A, 
Sadowsky MJ. Strain tracking reveals the determinants 
of bacterial engraftment in the human gut following 
Fecal microbiota transplantation. Cell Host Microbe. 
2018;23:229–240.e5. doi:10.1016/j.chom.2018.01.003.
18. Li SS, Zhu A, Benes V, Costea PI, Hercog R, 
Hildebrand F, Huerta-Cepas J, Nieuwdorp M, 
Salojärvi J, Voigt AY, et al. Durable coexistence of 
donor and recipient strains after fecal microbiota 
transplantation. Science. 2016;352:586–589. 
doi:10.1126/science.aad8852.
19.. Fadlallah J, Dorgham K, Autaa G, Gouas D, Almeida M, 
Lepage P, Pons N. Microbial ecology perturbation in 
human IgA deficiency. Sci Transl Med. 2018;10(439): 
eaan127.
20. Scully EP, Haverfield J, Ursin RL, Tannenbaum C, 
Klein SL. Considering how biological sex impacts 
immune responses and COVID-19 outcomes. Nat Rev 
Immunol. 2020;20(7): 442-447.
21. Lawley TD, Clare S, Walker AW, Stares MD, 
Connor TR, Raisen C, Goulding D, Rad R, 
Schreiber F, Brandt C, et al. Targeted restoration of 
the intestinal microbiota with a simple, defined bacter-
iotherapy resolves relapsing clostridium difficile disease 
in Mice. PLoS Pathog. 2012;8:e1002995. doi:10.1371/ 
journal.ppat.1002995.
22. Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, 
Gobourne A, No D, Liu H, Kinnebrew M, Viale A, et al. 
Precision microbiome reconstitution restores bile acid 
mediated resistance to Clostridium difficile. Nature. 
2014;517:205–208.
23. Monaghan TM, Pučić-Baković M, Vučković F, Lee C, 
Kao D, Human Glycome Project. Decreased complexity 
of serum N-glycan structures associates with successful 
fecal microbiota transplantation for recurrent clostri-
dioides difficile infection. Gastroenterology. 
2019;157:1676–1678.e3.
GUT MICROBES e1862027-11
24. Monaghan T, Jilani T, Frankowski M, Pomenya O, 
Yau TO, Christodoulou N, Hatziapostolou M, 
Wojcik I, Pucic-Bakovic M, Vuckovic F, et al. OTH- 
08 Circulating microRNAs linked to immunometabolic 
traits associate with faecal microbiota transplantation 
for clostridioides difficile infection. Gut. 2019;68:A185.
25. JAK M, Mullish BH, Pechlivanis A, Liu Z, 
Brignardello J, Kao D, Holmes E, Li JV, Clarke TB, 
Thursz MR, et al. Inhibiting growth of clostridioides 
difficile by restoring valerate, produced by the intestinal 
microbiota. Gastroenterology. 2018;155:1495–1507.e15.
26. Churchward MA, Michaud ER, Blanco JM, Garcia-Perez I, 
Mullish BH, Marchesi J, Xu H, Kao DH, Todd K. Sa1924 – 
effect of short chain fatty acids on gut-brain axis using 
a microglial cell model. Gastroenterology. 2019;156:S–455. 
doi:10.1016/S0016-5085(19)37990-9.
27. Wu W, Sun M, Chen F, Cao AT, Liu H, Zhao Y, 
Huang X, Xiao Y, Yao S, Zhao Q, et al. Microbiota 
metabolite short-chain fatty acid acetate promotes 
intestinal IgA response to microbiota which is mediated 
by GPR43. Mucosal Immunol [Internet]. 2016. [cited 
2016 Dec 19]. http://www.nature.com/doifinder/10. 
1038/mi.2016.114.
28. Frisbee AL, Petri WA. Considering the immune system 
during Fecal microbiota transplantation for clostri-
dioides difficile infection. Trends Mol Med. 
2020;26:496–507. doi:10.1016/j.molmed.2020.01.009.
29. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, 
Abnet CC, Al-Ghalith GA, Alexander H, Alm EJ, 
Arumugam M, Asnicar F, et al. Reproducible, interac-
tive, scalable and extensible microbiome data science 
using QIIME 2. Nat Biotechnol. 2019;37:852–857. 
doi:10.1038/s41587-019-0209-9.
30. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, 
Johnson AJA, Holmes SP. DADA2: high resolution 
sample inference from Illumina amplicon data. Nat 
Methods. 2016;13:581. doi:10.1038/nmeth.3869.
31. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, 
Yarza P, Peplies J, Glöckner FO. The SILVA ribosomal 
RNA gene database project: improved data processing 
and web-based tools. Nucleic Acids Res. 2012;41:D590– 
6. doi:10.1093/nar/gks1219.
32. McMurdie PJ, Holmes S, Watson M. phyloseq: an 
R package for reproducible interactive analysis and gra-
phics of microbiome census data. Plos One. 2013;8: 
e61217. doi:10.1371/journal.pone.0061217.
33. Janzon A, Goodrich JK, Koren O, TEDDY Study Group, 
Waters JL, Ley RE. Interactions between the gut microbiome 
and mucosal immunoglobulins A, M, and G in the develop-
ing infant gut. mSystems. 2019;4(6): e00612-19.
34. Kozich JJ, Westcott SL, Baxter NT, Highlander SK, 
Schloss PD. Development of a dual-index sequencing 
strategy and curation pipeline for analyzing amplicon 
sequence data on the Miseq illumina sequencing 
platform. Appl Environ Microbiol. 2013;79:5112–5120. 
doi:10.1128/AEM.01043-13.
35. García-Villalba R, Giménez-Bastida JA, 
García-Conesa MT, Tomás-Barberán FA, Carlos 
Espín J, Larrosa M. Alternative method for gas 
chromatography-mass spectrometry analysis of 
short-chain fatty acids in faecal samples. J Sep Sci. 
2012;35:1906–1913.
36. Moreau NM, Goupry SM, Antignac JP, Monteau FJ, Le 
Bizec BJ, Champ MM, Martin LJ, Dumon HJ. 
Simultaneous measurement of plasma concentrations and 
13C-enrichment of short-chain fatty acids, lactic acid and 
ketone bodies by gas chromatography coupled to mass 
spectrometry. J Chromatogr B Analyt Technol Biomed Life 
Sci. 2003;784:395–403. doi:10.1016/S1570-0232(02)00827-9.
37. Pacyna AD, Jakubas D, Ausems ANMA, Frankowski M, 
Ż P, Wojczulanis-Jakubas K. Storm petrels as indicators 
of pelagic seabird exposure to chemical elements in the 
Antarctic marine ecosystem. Sci Total Environ. 
2019;692:382–392. doi:10.1016/j.scitotenv.2019.07.137.
e1862027-12 K. E. HUUS ET AL.
